Hot Healthcare Stock Review; Boston Scientific Climbs on Better-than-expected Q4 Results
  • Stock Alert for Boston Scientific Corp. (BSX)
  • United States Steel Corporation (X) Reports Q2 Results
  • " />

    Boston Scientific Corporation (BSX) Reports Q2 Results

    Boston Scientific Corporation (BSX) Reports Q2 Results

    Boston Scientific Corporation (NYSE: BSX) has reported its second-quarter financial results. The company reported second-quarter net sales of $1.928 billion, down from $2.074 billion reported for the same period last year.

    The company reported that it maintained a 38% market share in the global drug-eluting stent (DES) market. The second quarter also saw the launch of TAXUS® Element™ Paclitaxel-Eluting Coronary Stent System in the European Union (EU) and other CE mark countries.

    Boston Scientific also refinanced debt maturing in 2011 and ended the quarter with $1 billion in cash on hand. The second quarter also saw the company increase its global Endoscopy sales by 8%. The company also initiated the PLATINUM PLUS “all comers” clinical trial comparing the performance of its PROMUS® Element™ Everolimus-Eluting Coronary Stent System to the Xience Prime™ Everolimus-Eluting Coronary Stent System.

    Boston Scientific reported second-quarter net income of $98 million, or $0.06 per share. The results included goodwill impairment-related credit, restructuring charges and amortization expense. The company reported adjusted second-quarter net income of $190 million, or $0.12 per share. For the same period last year, the company had reported net income of $158 million, or $0.10 per share, while its adjusted net income stood a $297 million, or $0.20 per share.

    Commenting on the second-quarter financial results, Ray Elliott, President and CEO of Boston Scientific Corporation, said that he was proud of the way the company executed in a number of important areas during the quarter. Elliot said that the company finished the quarter ahead of expectations in CRM. He also said that the continued success of its PROMUS Element rollout in Europe was a strong example of outstanding execution by the company.

    For the third quarter, Boston Scientific Corporation expects net sales of $1.850-$1.925 billion. The company expects adjusted earnings of $0.10-$0.13 per share for the third quarter. Third-quarter GAAP earnings per share are expected to come in between $0.01 per share and $0.05 per share.

    For the full year, Boston Scientific has revised its sales estimates. The company now expects sales to come in between $7.6 billion and $7.9 billion.

    Shares of Boston Scientific Corporation are down in today’s trading. The stock touched a low of $5.82 today. At last check, it was down 3.67% to $6.04, with volume up from daily average of 21.37 million to 35.66 million. The stock has a 52-week range of $5.41-$11.77 and currently trades below its 50-day and 200-day moving averages.

    About is committed to producing the highest-quality insight and analysis of small cap stocks, emerging technology stocks, hot penny stocks and helping investors make informed decisions. Our focus is primarily on the underserved OTC stocks market, or “penny stock” market, which has traditionally been shunned by Wall Street. We have particular expertise with renewable energy stocks, biotech stocks, oil stocks, green energy stocks and internet stocks. There are many hot penny stock opportunities present in the OTC market everyday and we seek to exploit these hot stock gains for our members before the average daytrader is aware of them.

    MicroStockProfit Disclaimer

    This newsletter is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. is a wholly-owned subsidiary of BlueWave Advisors.

    While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

    Leave a Reply

    Your email address will not be published. Required fields are marked *